553
Participants
Start Date
February 20, 2023
Primary Completion Date
October 10, 2024
Study Completion Date
July 11, 2028
ART
Standard of care ART, per approved product list, taken orally
DOR/ISL
Combination of 100 mg doravirine (DOR) with 0.25 mg Islatravir (ISL) in tablet form, taken orally, once daily.
CHUV (centre hospitalier universitaire vaudois) ( Site 4006), Lausanne
Hôpitaux Universitaires de Genève (HUG)-Infectious Disease Department ( Site 4004), Geneva
Holdsworth House Medical Practice ( Site 4200), Darlinghurst
St Vincent's Hospital-IBAC ( Site 4203), Sydney
Perinatal HIV Research Unit (PHRU)-Adult Treatment and Research ( Site 3905), Johannesburg
Helen Joseph Hospital ( Site 3910), Johannesburg
Ezintsha-Clinical Research Site ( Site 3907), Johannesburg
Inselspital Bern-Inselspital Infektiologie ( Site 4003), Bern
Prahran Market Clinic ( Site 4202), Melbourne
Holdsworth House Medical Practice - Brisbane ( Site 4201), Brisbane
Royal Brisbane and Women's Hospital-Infectious Diseases Research ( Site 4204), Brisbane
University Hospital Basel-Infectiology ( Site 4002), Basel
Wentworth Hospital ( Site 3904), Durban
Ospedale Regionale di Lugano, Sede Civico-Servizio Malattie Infettive ( Site 4005), Lugano
Family Clinical Research Unit (Fam-Cru)-Adult Infectious Diseases ( Site 3908), Cape Town
Be Part Yoluntu Centre ( Site 3901), Paarl
Desmond Tutu Health Foundation ( Site 3902), Cape Town
UniversitätsSpital Zürich ( Site 4000), Zurich
Josha Research ( Site 3903), Bloemfontein
Penn Medicine: University of Pennsylvania Health System-Perelman Center for Advanced Medicine ( Site, Philadelphia
Georgetown University Medical Center ( Site 3006), Washington D.C.
Infectious Disease Specialists of Atlanta ( Site 3003), Decatur
Chatham County Health Department - Chatham CARE Center-Infectious Disease ( Site 3028), Savannah
Orlando Immunology Center ( Site 3004), Orlando
Triple O Research Institute, P.A ( Site 3026), West Palm Beach
CAN Community Health - Sarasota ( Site 3017), Sarasota
Midway Immunology and Research Center ( Site 3009), Ft. Pierce
DCOL Center for Clinical Research ( Site 3022), Longview
The Crofoot Research Center ( Site 3040), Houston
Central Texas Clinical Research ( Site 3015), Austin
Kaiser Permanente-Infectious Disease ( Site 3014), Los Angeles
Palmtree Clinical Research ( Site 3032), Palm Springs
Zuckerberg San Francisco General Hospital and Trauma Center-UCSF ID Clinical Trials Center ( Site 30, San Francisco
Fundacion Valle del Lili- CIC ( Site 3302), Santiago de Cali
ID Care ( Site 3041), Hillsborough
Hamilton Health Sciences- Urgent Care Centre-SIS Clinic ( Site 3104), Hamilton
Maple Leaf Research ( Site 3103), Toronto
Toronto General Hospital ( Site 3102), Toronto
Clinique de médecine Urbaine du Quartier Latin ( Site 3101), Montreal
Clinique Medicale lActuel-Clinical Research ( Site 3100), Montreal
Ciensalud Ips S A S ( Site 3300), Barranquilla
Clinica de la Costa S.A.S. ( Site 3305), Barranquilla
National Hospital Organization Nagoya Medical Center ( Site 4403), Nagoya
Tokyo Medical University Hospital ( Site 4404), Shinjuku-ku
Center Hospital of the National Center for Global Health and Medicine ( Site 4401), Shinjyuku-ku
Private Practice Dr. Marleen de Jager ( Site 3900), Pretoria
Brighton and Sussex University Hospitals NHS Trust ( Site 4104), East Sussex
North Manchester General Hospital ( Site 4107), Crumpsall
Royal London Hospital ( Site 4100), London
Royal Free Hospital ( Site 4101), London
Royal Victoria Infirmary ( Site 4105), Newcastle upon Tyne
King's College Hospital ( Site 4108), London
Heartlands Hospital ( Site 4102), Birmingham
Merck Sharp & Dohme LLC
INDUSTRY